We are now enrolling qualified sites for the CorEvitas Systemic Lupus Erythematosus (SLE) Registry. If you are interested in becoming a participating site, please get in touch using the link below.
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease in which the immune system mistakenly attacks the body’s own tissues and organs, causing inflammation and damage. It can affect multiple organ systems, including the skin, joints, kidneys, heart, lungs, brain, and blood cells. SLE is the most common and severe type of lupus and is characterized by periods of flares and remissions. Common symptoms include fatigue, joint pain, skin rashes (such as the characteristic butterfly rash), and kidney issues. SLE can vary in severity, with treatment focused on managing symptoms and reducing inflammation. While SLE is a lifelong condition, early diagnosis and effective management allow many people with the disease to live relatively normal lives, though some may experience serious complications over time.
The SLE registry prospectively collects detailed patient-level data, enabling assessment of the natural history of the disease, treatment patterns, real-world safety of medications used, disease burden and unmet needs in patients living with SLE. Granular, longitudinal outcome measures are collected during regular visits, including clinician-reported SLE outcomes, biologics and lab measures, and patient-reported outcomes assessing symptom impact and quality of life.
Read the press release, here.
Clinical Director, Lupus Center & Director, Rheumatology Clinical Trials
Professor of Medicine, Columbia University Medical Center
Chief, Division of Rheumatology
Beth Israel Deaconess Medical Center
Professor of Medicine, Harvard Medical School
